Sign In
Buy CVS
$98.32
-0.84 (-0.85%)
At Close: Jun 18, 2026
Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
04:41pm, Wednesday, 20'th Aug 2025
CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medic
Should You Invest in CVS Health (CVS) Based on Bullish Wall Street Views?
10:31am, Wednesday, 20'th Aug 2025
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
CVS unit must pay $290 million in drug whistleblower lawsuit, judge rules
10:06am, Wednesday, 20'th Aug 2025
A federal judge ordered CVS Health's pharmacy benefit manager unit to pay $289.9 million in damages and penalties after it overcharged Medicare for prescription drugs.
CVS Health upgraded by UBS on strong execution, margin improvement
03:41pm, Monday, 18'th Aug 2025
CVS Health Corp (NYSE:CVS) has been upgraded by UBS analysts who cited greater confidence in the company's recovery trajectory and multiple levers for earnings growth. The analysts upped their rating
CVS cannot obtain AIG, Chubb opioid coverage, top Delaware court rules
02:32pm, Monday, 18'th Aug 2025
CVS Health is not entitled to coverage from insurers, including AIG and Chubb , against thousands of lawsuits over its role in the nation's opioid crisis, Delaware's highest court ruled on Monday.
Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
10:01am, Monday, 18'th Aug 2025
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
CVS Health: Outlier In Healthcare Implosion - Further Margin Recovery Ahead
09:45am, Monday, 18'th Aug 2025
CVS has emerged as an outlier during the ongoing implosion observed in the healthcare insurance sector, as they drive improved YoY margins despite the rising medical costs. This is on top of the somew
CVS Health: Health Insurers Get Buffett's Stamp Of Approval (Rating Upgrade)
09:09am, Saturday, 16'th Aug 2025
Super investors like Buffett and Michael Bury piled heavily into UnitedHealthcare in Q2, signalling confidence that the sector's business model remains intact despite recent headwinds. CVS has emerged
Gill: We're at a real inflection point for healthcare
10:35am, Friday, 15'th Aug 2025
Lisa Gill, JP Morgan healthcare analyst, on “Worldwide Exchange,” says healthcare is at an inflection point, with UnitedHealth poised for long-term gains as big investors bet on a turnaround.
CVS Advances Digital Efforts to Simplify Healthcare Experience
09:31am, Thursday, 14'th Aug 2025
CVS Health commits $20B to build an open health platform, joining tech giants in a push to streamline patient care access nationwide.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CVS (CVS) To Contact Him Directly To Discuss Their Options
My Dividend Stock Portfolio: New July Dividend Record - 100 Holdings With 12 Buys
08:15am, Wednesday, 13'th Aug 2025
July saw strong market gains, especially in tech, but finding bargains is tough as indices approach all-time highs. I focused July investments on high-yield BDCs like OBDC, MFIC, and BXSL, maintaining
CVS or DHR: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 11'th Aug 2025
Investors with an interest in Medical Services stocks have likely encountered both CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
3 Strong Buy High-Yield Dividend Stocks With Over 40% Upside Potential
09:20am, Monday, 11'th Aug 2025
Investors love dividend stocks, especially those with high yields, because they provide a substantial income stream and offer significant total return potential.
Is CVS a Smart Buy Now on Strong Q2, Low Valuation & Long-Term Upside?
04:00pm, Thursday, 07'th Aug 2025
CVS appears well-poised on strong Q2 revenue growth, raised full-year guidance and momentum in key healthcare segments.
